- Research Article
22
- 10.1542/pir.34.5.203
Type 1 Diabetes Mellitus
- May 01, 2013
- Pediatrics In Review
- Justin M Gregory + 2 more +2
Type 1 Diabetes Mellitus
In the early 1960s, Dr. Arnold Kadish developed the first insulin pump, which was the size of a Marine backpack.1 Over the years, insulin pumps have become much more refined and have decreased in bulk to the size and weight of a small pager. Insulin pump therapy, also known as continuous subcutaneous insulin infusion, is no longer seen as experimental and controversial, but rather is viewed as an acceptable alternative to multiple daily injection (MDI) therapy in the management of insulin-dependent diabetes2 (Table 1).3 The insulin pump is an electromechanical device that mimics the body's natural insulin secretion from pancreatic β-cells by subcutaneously delivering rapid-acting insulin both at preset continuous basal rates and in extra bolus doses at mealtimes on demand.4 Insulin pumps allow for up to 24 different hourly basal rates in a 24-hour period. For bolus doses, pump users input their current blood glucose level and the number of carbohydrates they will consume, and the pump customizes their dose based on insulin currently on board (i.e., the remaining active insulin from the previous dose), their individualized insulin-to-carbohydrate ratio, and their individualized insulin sensitivity factor (i.e., their expected drop in blood glucose from 1 unit of insulin).1,5 Thus, insulin pumps are able to deliver insulin in a more physiological manner than other injection-based insulin regimens.5 In the late 1970s, results of the first human trials of insulin pump therapy were published. This was followed by numerous additional studies comparing insulin pump therapy to traditional MDI regimens with regard to long-term glycemic control and minimization of hypoglycemia.6–11 Then, in 1993, the Diabetes Control and Complications Trial12 confirmed the importance of intensive glycemic control using either insulin pump therapy or an MDI regimen along with frequent self-monitoring of …
Type 1 Diabetes Mellitus
Type 1 Diabetes Mellitus
Postnatal growth of infants with neonatal diabetes: Insulin pump (CSII) versus Multiple Daily Injection (MDI) therapy
Background: Permanent neonatal diabetes mellitus (PNDM) is characterized by the onset of hyperglycemia within the first six months of life. Their diabetes is associated with partial or complete insulin deficiency with variable degree of intrauterine growth retardation. Insulin therapy corrects the hyperglycemia and results in improvement of growth. However, no studies have reported the longitudinal growth of these infants (head circumference, length and weight gain) after starting insulin therapy. Patients and methods: We assessed the growth parameters weight (Wt), Length (L) and head circumference (HC) in 9 infants with PNDM, during the first 2 years of their postnatal life. Five infants were on insulin pump therapy (CSII) and 4 were on multiple doses of insulin injection (MDI) therapy. Results: On insulin therapy for 20±4 months catch-up growth occurred in the majority of infants. L-SDS increased from -1.45 to -0.65 , HC-SDS from -2.3 to - 0.51 and Wt-SDS increased from -1.94 to - 0.7 at the end of the 20±4 months of age, after starting insulin therapy. Two out of 9 infants had a L-SDS <-2 , in 4 Wt-SDS was <-2 and in 1 the HC-SDS was <-2 at at 20±4 months of postnatal growth. The level of HbA1c was lower in infants on CSII compared to those on MDI (9.6±1%) compared to those on MDI (10.2±2%). However, growth parameters improved significantly in both groups (CSII and MDI) with no significant difference among them. Conclusions: Infants with PNDM with positive anti-GAD and antiTPO were diagnosed later and their intra-uterine and postnatal growth differed compared to those with negative antibodies. The majority of infants with PNDM exhibited significant catch up growth within the first two years of life irrespective of the etiology of diabetes. HbA1c appeared to be better in infants with PNDM on CSII therapy when compared to those on MDI therapy. (www.actabiomedica.it)
Read moreClinical effectiveness and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes: systematic review and economic evaluation.
The National Institute for Health and Clinical Excellence (NICE) was reviewing its previous guidance on continuous subcutaneous insulin infusion (CSII). The review provided an assessment of evidence which had been published since the previous NICE appraisal (TA 151) in 2007. To examine the clinical effectiveness and cost-effectiveness of using CSII to treat diabetes. To update the previous assessment report by reviewing evidence that has emerged since the last appraisal, and to take account of developments in alternative therapies, in particular the long-acting analogue insulins, which cause fewer problems with hypoglycaemia. A systematic review of the literature and an economic evaluation were carried out. The bibliographic databases used were MEDLINE and EMBASE, 2002 to June 2007. The Cochrane Library (all sections), the Science Citation Index (for meeting abstracts only) and the website of the 2007 American Diabetes Association were also searched. The primary focus for type 1 diabetes mellitus (T1DM) was the comparison of CSII with multiple daily injection (MDI), based on the newer insulin analogues, but trials of neutral protamine Hagedorn (NPH)-based MDI that had been published since the last assessment were identified and described in brief. For type 2 diabetes mellitus (T2DM), all trials of MDI versus CSII were included, whether the long-acting insulin was analogue or not, because there was no evidence that analogue-based MDI was better than NPH-based MDI. Trials that were shorter than 12 weeks were excluded. Information on the patients' perspectives was obtained from four sources: the submission from the pump users group--Insulin Pump Therapy (INPUT); interviews with parents of young children who were members of INPUT; some recent studies; and from a summary of findings from the previous assessment report. Economic modelling used the Center for Outcomes Research (CORE) model, through an arrangement with the NICE and the pump manufacturers, whose submission also used the CORE model. The 74 studies used for analysis included eight randomised controlled trials (RCTs) of CSII versus analogue-based MDI in either T1DM or T2DM, eight new (since the last NICE appraisal) RCTs of CSII versus NPH-based MDI in T1DM, 48 observational studies of CSII, six studies of CSII in pregnancy, and four systematic reviews. The following benefits of CSII were highlighted: better control of blood glucose levels, as reflected by glycated haemoglobin (HbA1c) levels, with the size of improvement depending on the level before starting CSII; reduction in swings in blood glucose levels, and in problems due to the dawn phenomenon; fewer problems with hypoglycaemic episodes; reduction in insulin dose per day, thereby partly off-setting the cost of CSII; improved quality of life, including a reduction in the chronic fear of severe hypoglycaemia; more flexibility of lifestyle--no need to eat at fixed intervals, more freedom of lifestyle and easier participation in social and physical activity; and benefits for the patients' family. The submission from INPUT emphasised the quality of life gains from CSII, as well as improved control and fewer hypoglycaemic episodes. Also, there was a marked discrepancy between the improvement in social quality of life reported by successful pump users, and the lack of convincing health-related quality of life gains reported in the trials. With regard to economic evaluation, the main cost of CSII is for consumables, such as tubing and cannulas, and is about 1800-2000 pounds per year. The cost of the pump, assuming 4-year life, adds another 430-720 pounds per annum. The extra cost compared with analogue-based MDI averages 1700 pounds. Most studies, assuming a reduction in HbA1c level of 1.2%, found CSII to be cost-effective. The most important weakness of the evidence was the very small number of randomised trials of CSII against the most modern forms of MDI, using analogue insulins. Based on the totality of evidence, using observational studies to supplement the limited data from randomised trials against best MDI, CSII provides some advantages over MDI in T1DM for both children and adults. However, there was no evidence that CSII is better than analogue-based MDI in T2DM or in pregnancy. Further trials with larger numbers and longer durations comparing CSII and optimised MDI in adults, adolescents and children are needed. In addition, there should be a trial of CSII versus MDI with similar provision of structured education in both arms. A trial is also needed for pregnant women with pre-existing diabetes, to investigate using CSII to the best effect.
Read moreUse of rapid-acting insulin analogues in the treatment of patients with type 1 and type 2 diabetes mellitus: Insulin pump therapy versus multiple daily injections
Use of rapid-acting insulin analogues in the treatment of patients with type 1 and type 2 diabetes mellitus: Insulin pump therapy versus multiple daily injections
Read moreSystematic review and meta-analysis of insulin pump therapy in children and adolescents with type 1 diabetes
<h3>Aims</h3> Continuous subcutaneous infusion of insulin (CSII) via an insulin pump is believed to provide more physiological and flexible control of type 1 diabetes compared with injection regimens such as intensive multiple daily injection (MDI) regimens. However, a number of small underpowered randomised trials have failed to provide conclusive evidence for this. The authors undertook a systematic review and meta-analysis to better estimate the effectiveness and safety of CSII compared with MDI. <h3>Methods</h3> A systematic review was undertaken to identify randomised controlled trials (RCT) and unrandomised prospective controlled studies comparing CSII with MDI in subjects ≤18 years with established type 1 diabetes (≥6 months) and of duration ≥3 months. Meta-analysis for haemoglobin A1c (HbA1c), hypoglycaemia and quality of life outcomes was undertaken using random effects model in Review Manager 5.0.22. <h3>Results</h3> 10 RCT s (n=307) and five prospective studies (n=318) were included. Overall quality of trials was poor. Glycaemic control: At 6 months CSII was shown to provide a minor benefit in reduced HbA1c over MDI in RCTs (mean pooled difference = −0.24% (95% CI −0.48 to −0.00); minimal heterogeneity (I2=0%)) and prospective studies (−0.32 (95% CI −0.62 to −0.03); I2=0%). These benefits remained at 12 months in prospective studies although they failed to reach significance. There were insufficient data for analysis in RCTs at 12 months. Hypoglycaemia: CSII was associated with reduced risk of severe hypoglycaemia at 6 months in RCTs (RR 0.66 (95% CI 0.32 to 1.36); not significant) and at 12 months in prospective studies (RR 0.50 (95% CI 0.28 to 0.88); I2=0%). Quality of life: Data were sparse and inappropriate for meta-analysis. <h3>Conclusion</h3> CSII in children and adolescents is associated with small mean reduction in HbA1c and a decreased risk of severe hypoglycaemia when compared with MDI in relatively unselected populations during short-term follow-up. There is little evidence that CSII improves quality of life compared with MDI. Larger better quality trials with longer-term follow-up are needed to establish the benefit of CSII in paediatric populations.
Read moreAccess to insulin pump therapy and continuous glucose monitoring - is it an even playing field?
Diabet. Med. 29, 971 (2012) Insulin therapy using an insulin injection was introduced in 1922. Progress towards a more physiological approach to insulin replacement has been painfully slow. One advance has been the use of continuous subcutaneous insulin infusion (CSII or insulin pumps) with or without glucose sensor augmentation. However, this therapeutic option is expensive and requires a trained multidisciplinary team to deliver an insulin pump service. It is therefore important to consider who would most benefit from such therapy and its cost-effectiveness. The availability of insulin pumps as a therapeutic option for the treatment of diabetes varies both between and within countries depending on the health system and its affordability for that country. In this month’s issue, Carlsson and colleagues (page 1055) examine the availability of insulin pump therapy in people with Type 1 diabetes attending 10 hospital outpatient clinics in Sweden. The use of insulin pumps varied between clinics and women were 1.5-fold more likely to use such therapy. Other features associated with pump use were a higher HbA1c at baseline, lower creatinine, high and low insulin doses, and younger age. People with Type 1 diabetes aged 20–30 years were two times more likely to begin to use insulin pumps than those aged 40–50 years. In the UK there are national guidelines (the National Institute for Health and Clinical Excellence; NICE) that recommend consideration of pump therapy in people with Type 1 diabetes on multiple daily injections with HbA1c > 69 mmol/mol (8.5%) despite the person trying to improve their diabetes control or in those in whom target HbA1c cannot be reached because of hypoglycaemia. The recommendations are even more relaxed in children. NICE also states that insulin pump therapy should only be started by a trained team that includes a doctor who specializes in insulin pump therapy, a diabetes nurse and a dietician. It is then recommended that the therapy should only be continued if there is a sustained improvement in HbA1c and/or less hypoglycaemia; quality of life should also be added to this list. An audit of pump services is currently being undertaken in the UK but it is likely to find that access is variable between sites, with some regions still not having access to a pump service as the commissioners of health care will not fund the service that requires not only the cost of the pump and its consumables but all members of the pump team, including the funding of educational packages. The availability of an insulin pump for a person with Type 1 diabetes then becomes a post-code lottery. This is an unacceptable state of affairs. Some patients with Type 1 diabetes do not want to use an insulin pump, but would consider the use of a continuous glucose monitoring system (CGMS). Unfortunately, there is no formal guidance on this issue in many countries, which makes it even more difficult for this to be considered an option, despite the wishes of those living with diabetes and health professionals advising on best practice.
Read moreComparison of Continuous Subcutaneous Insulin Infusion versus Basal/Bolus Insulin Injections for Treatment of Type 1 Diabetes in Clinical Practice
It is now generally agreed that to achieve optimal glycemic control, patients with type 1 diabetes should be treated with intensive insulin therapy. This can be achieved by a continuous subcutaneous insulin infusion (CSII) or by multiple daily injections (MDI) using a combination of long-acting basal insulin (glargine or detemir) and a short-acting insulin (lispro, aspart, or glulisine) to control postprandial hyperglycemia. However, it remains controversial whether these two modalities are equally effective or if one is superior to the other. One meta-analysis1 and the 5-nations trial2 concluded that CSII resulted in better glycemic control compared to MDI. However, older insulins (neutral protamine Hagedorn or regular) and outdated pump technologies were used in these studies. Other studies have shown CSII to be equally effective3 or CSII being superior4 to MDI. Although a more recent meta-analysis also showed that the frequency of severe hypoglycemia in type 1 diabetes was reduced markedly in trials during CSII compared with MDI based on isophane and lente insulins, the authors acknowledged that they did not find any trials comparing CSII and MDI based on the newer long-acting insulin analogs where severe hypoglycemia could be analyzed. Moreover, their conclusions on hemoglobin A1c (HbA1c) were based on a relatively small number of trials concerning glargine and none using detemir.5 In addition, it is not clear if one of these two treatment modalities is superior to the other in routine clinical practice. We therefore compared the degree of glycemic control achieved, frequency and severity of hypoglycemic episodes, and perception of quality of life achieved by CSII versus MDI in our practice. We sent letters inviting all patients being treated with CSII or MDI in our practice that had been followed for at least 2 years—113 letters were sent to pump patients and 137 to patients on MDI. Fifty-three patients treated with CSII using insulin lispro or aspart and 54 patients treated with MDI therapy (glargine and either insulin lispro or aspart) agreed to participate. Hypoglycemic episodes were self-reported as mild or severe (requiring third-party help). Life satisfaction, impact, and worry related to diabetes were assessed by the diabetes quality of life questionnaire.6 The patient demographics and results of the study are shown in Table 1. Table 1. Demographics and Results Comparing CSII with MDI The mean HbA1c was significantly lower in the CSII group. Episodes of severe hypoglycemia were less frequent, and overall satisfaction was greater in the CSII group compared to the MDI group. These findings are similar to those seen in randomized controlled trials.1,2,4,5 We acknowledge that our sample was not a randomized sample and although we did not evaluate the socioeconomic status of patients, it is apparent that only those who could afford the pumps would have been on CSII therapy. We conclude that CSII therapy is associated with better glycemic control, fewer episodes of severe hypoglycemia, and higher life satisfaction compared to MDI in patients with type 1 diabetes in a routine clinical practice.
Read moreUse of continuous subcutaneous insulin infusion (insulin pump) therapy in the hospital: a review of one institution's experience.
This article reviews the performance of our hospital's inpatient insulin pump policy. Twenty-five hospital admissions of 21 unique patients receiving outpatient insulin pump therapy were reviewed. Between November 1, 2005, and November 30, 2006, there were 25 hospital admissions involving 21 patients receiving outpatient insulin pump therapy. The average age and duration of diabetes among these 21 patients was 50 and 29 years, respectively; 67% were women, 90% had type 1 diabetes, and all were white. The mean length of hospital stay was 4 days, and the average reported length of insulin pump therapy was 4 years. Patients in 16 of the admissions were identified as candidates for continued use of the insulin pump during the hospital stay. Over 90% of patients remaining on the insulin pump had documentation by nursing of the presence of the pump at the time of admission; 100% of the patients had an admission glucose recorded; 88% had a record of signed patient consent; 81% had evidence of completed preprinted insulin pump orders; 75% received a required endocrine consultation; and 75% of cases had documentation of completed bedside flow sheet. A high frequency of both hypoglycemic and hyperglycemic events occurred in the patients; however, no adverse events were related directly to the insulin pump. Insulin pump therapy can be safely continued in the hospital setting. While staff compliance with required procedures was high, there was still room for improvement. More data are needed, however, on whether this method of insulin delivery is effective for controlling hyperglycemia in hospitalized patients.
Read moreWho gains clinical benefit from using insulin pump therapy? A qualitative study of the perceptions and views of health professionals involved in the Relative Effectiveness of Pumps over MDI and Structured Education (REPOSE) trial.
To explore health professionals' views about insulin pump therapy [continuous subcutaneous insulin infusion (CSII)] and the types of individuals they thought would gain greatest clinical benefit from using this treatment. In-depth interviews with staff (n = 18) who delivered the Relative Effectiveness of Pumps Over MDI and Structured Education (REPOSE) trial. Data were analysed thematically. Staff perceived insulin pumps as offering a better self-management tool to some individuals due to the drip feed of insulin, the ability to alter basal rates and other advanced features. However, staff also noted that, because of the diversity of features on offer, CSII is a more technically complex therapy to execute than multiple daily injections. For this reason, staff described how, alongside clinical criteria, they had tended to select individuals for CSII in routine clinical practice based on their perceptions about whether they possessed the personal and psychological attributes needed to make optimal use of pump technology. Staff also described how their assumptions about personal and psychological suitability had been challenged by working on the REPOSE trial and observing individuals make effective use of CSII who they would not have recommended for this type of therapy in routine clinical practice. Our findings add to those studies that highlight the difficulties of using patient characteristics and variables to predict clinical success using CSII. To promote equitable access to CSII, attitudinal barriers and prejudicial assumptions amongst staff about who is able to make effective use of CSII may need to be addressed.
Read moreCombined insulin pump therapy with real-time continuous glucose monitoring significantly improves glycemic control compared to multiple daily injection therapy in pump naïve patients with type 1 diabetes; single center pilot study experience.
This study assessed the safety and clinical effectiveness of the training protocol for initiating insulin pump therapy with real-time continuous glucose monitoring (MiniMed Paradigm REAL-Time System) in a stepwise approach on pump naive subjects with type 1 diabetes compared to a control group who remained on multiple daily injection (MDI) therapy. This was a 15-week treat-to-target pilot study of 16 adult subjects (n = 50% male, age 45.9 +/- 16 years) with type 1 diabetes (duration of diabetes 21.9 +/- 11 years) on MDI therapy with hemoglobin A1c levels at or above 7.5% at baseline. Subjects were randomized to either the study arm (using a combined insulin pump and real-time continuous glucose monitoring system) or the control arm [which continued on MDI therapy with self-monitored blood glucose (SMBG) only]. All subjects dosed insulin according to results of SMBG by finger stick and uploaded data into the CareLink data management software. Significant improvements in glycemic control were observed from baseline in both study groups-study arm: pre-A1c 9.45 +/- 0.55 and post-A1c 7.4 +/- 0.66 (p = 0.00037); control arm: pre-A1c 8.58 +/- 1.30 and post-A1c 7.5 +/-1.01 (p = 0.04). Both arms had no incidence of severe hypoglycemia. In this pilot study, the Paradigm REAL-Time System was initiated safely and effectively in type 1 diabetes patients who were pump naïve using a stepwise educational protocol.
Read moreThe Impact of Insulin Pump Therapy on Glycemic Control and Acute Diabetes Complications in Type 1 Diabetes: Real-World Evidence From a Single Center
Background and objectivesThe adoption of insulin pumps in diabetes management has seen a significant rise globally, offering promising advancements in glycemic control. Despite this progress, notable disparities remain in the utilization of this technology across different populations. We hypothesized that insulin pump therapy improves glycemic control and reduces acute complications compared to multiple daily injection (MDI) therapy. This study aimed to assess the impact of insulin pump therapy on glycemic control and acute diabetes complications among patients with type 1 diabetes mellitus at King Fahad Armed Forces Hospital (KFAFH), Jeddah. We sought to compare patient outcomes before initiating insulin pump therapy (while on MDI insulin therapy), using Abbott FreeStyle Libre 2 continuous glucose monitoring (CGM), to their results after transitioning to insulin pump therapy for six months. The findings will contribute to understanding the effectiveness of this technology in a clinical setting and addressing gaps in its adoption.MethodsA cross-sectional study was conducted among patients with type 1 diabetes mellitus aged seven years and older who attended the Diabetes and Endocrine Department at KFAFH, Jeddah. Data were collected using a structured survey.ResultsThe study included 24 patients with type 1 diabetes mellitus, with a mean age of 22.79 ± 8.86 years and a mean BMI of 24.35 ± 4.96. The mean age at diagnosis was 12.25 ± 5.29 years. Most patients (n = 22, 91.7%) used the MiniMed™️ 780G system, which employs an advanced hybrid closed-loop (AHCL) algorithm. All participants underwent carbohydrate-counting sessions prior to the initiation of insulin pump therapy. After six months of insulin pump therapy, significant improvements (p<0.05) were observed in hemoglobin A1C (HbA1c) or glucose management indicator (GMI) levels, Percentage of time spent in target blood glucose range (TIR) per day, Percentage of time below target glucose range (TBR) per day, percentage of time very low below target glucose range per day, Frequency of hypoglycemia per week, diabetic ketoacidosis (DKA) admissions, and meal time flexibility. The findings will contribute to understanding the effectiveness of this technology in a clinical setting and addressing gaps in its adoptionConclusionsInsulin pump therapy is associated with improved and sustained glycemic control in patients with type 1 diabetes mellitus. Achieving optimal blood glucose levels is critical for reducing the risk of diabetes-related complications and lowering mortality rates. These improvements significantly enhance the quality of life and reduce the economic burden associated with diabetes management.
Read moreInsulin pump therapy in youth with type 1 diabetes: toward closed-loop systems
Introduction: Insulin pump technology has advanced considerably over the past three decades, leading to more favorable metabolic control and less hypoglycemic events when compared with multiple daily injection therapy. The use of insulin pumps is increasing, particularly in children and adolescents with type 1 diabetes.Areas covered: This review outlines recent developments in insulin pump therapy from a pediatric perspective. ‘Smart’ pumps, sensor-augmented pump therapy and threshold-suspend feature of insulin pumps are reviewed in terms of efficacy, safety and psychosocial impact. The current status of closed-loop systems focusing on clinical outcomes is highlighted.Expert opinion: Closed-loop insulin delivery is gradually progressing from bench to the clinical practice. Longer and larger studies in home settings are needed to expand on short- to medium-term outpatient evaluations. Predictive low glucose management and overnight closed-loop delivery may be the next applications to be implemented in daily routine. Further challenges include improvements of control algorithms, sensor accuracy, duration of insulin action, integration and size of devices and connectivity and usability. Gradual improvements and increasing sophistication of closed-loop components lie on the path toward unsupervised hands-off fully closed-loop system.
Read moreInsulin pump therapy in toddlers and preschool children with type 1 diabetes mellitus
Insulin pump therapy in toddlers and preschool children with type 1 diabetes mellitus
Use and Effectiveness of Continuous Subcutaneous Insulin Infusion (CSII) and Multiple Daily Insulin Injection Therapy (MIT) in Children, Adolescents and Young Adults with Type 1 Diabetes Mellitus.
Today continuous subcutaneous insulin infusion (CSII) is frequently used in children and adolescents with type 1 diabetes mellitus. The present cross-sectional trial aimed to document current practice, quality of diabetes control and incidence of acute complications in different age-groups under CSII vs. multiple daily insulin injection therapy (MIT). Moreover the survey analyzed socio-demographic backgrounds of the patients. A total of 901 patients (age 11.5±4.0, diabetes duration 4.0±3.6 years) was entered in the database. Clinical data, laboratory parameters and, using a standardized questionnaire, socio-demographic data were assessed. For age-related analyses patients were allocated to 4 groups: pre-school children (< 6 years), pre-adolescents (≥ 6 and<11 years), adolescents (≥ 11 and<16 years) and young adults (≥ 16 and<22 years). Of the cohort n=194 had a CSII, n=707 had a MIT. Patients with CSII vs. MIT had a longer diabetes duration, they used more frequently insulin analogues, performed more frequently blood-glucose self-tests and had a lower insulin dosage per kilogram body weight. In respect of HbA1c, the mean amplitude of blood-glucose excursions, but also of lipids, creatinine, microalbuminuria and blood pressure, there were no differences in neither age-group between patients with CSII and MIT. In patients with CSII and MIT, there was a tendency (p<0.05) towards an increase in HbA1c in adolescents and young adults and there was a decrease (p<0.05 for tendency) in the frequency of hypoglycaemia from the age group of young adults to pre-school children. Adolescents and young adults with CSII had a higher educational level. Pre-adolescents, adolescents and young adults with CSII have also better diabetes-related knowledge. Moreover, in all age-groups, the parents of patients with CSII had mostly a lower unemployment rate and higher educational levels. The present analyses demonstrate that in all age-groups CSII provides convenient and flexible insulin delivery during routine treatment of type 1 diabetes. There is reasonable quality of diabetes control accompanied by a low incidence of hypoglycaemia and ketoacidosis. However, under CSII and MIT there is an increase of HbA1c towards adolescence. It must also highlighted that CSII seems to be expansive and that CSII is more frequently used in patients with better educational levels and deriving from higher social classes.
Read morePoint: Are Insulin Pumps Underutilized in Type 1 Diabetes? Yes
Continuous subcutaneous insulin infusion (CSII), popularly called insulin pump therapy, has evolved from its invention in the 1970s as an experimental treatment designed to test the relationship between glycemic control and diabetic tissue complications (1) to its present status as a routine therapy for selected type 1 diabetic patients (2). However, the use of insulin pump therapy varies markedly throughout the world; there are some notable high-use countries, e.g., the U.S. and Israel, where it is estimated that ∼20% of type 1 diabetic patients use CSII (manufacturers’ estimates), whereas in other countries, such as the U.K. and Denmark, ∼1% use pump therapy (3). The reasons for this variation include the availability of financial resources and health care professionals to supervise CSII and a lack of knowledge on the effectiveness of CSII (3), but there is also disagreement on which diabetic subjects should be treated with CSII, as evidenced by both the different intercountry usage and the large number of reasons for starting insulin pump therapy (4–6). As noted by Schade and Valentine (7), “the challenge for the health care provider is to select the diabetic patients who will really benefit from pump usage.” What proportion and what types of type 1 diabetic patients should then be offered a trial of CSII on clinical grounds alone, leaving aside the legitimate issues of supply on the basis of patient preference and restrictions due to availability of funding and staffing? I shall argue that the target proportion best treated by CSII, or offered a trial of CSII, can be derived from an estimate of the effectiveness of this therapy compared with the best insulin injection treatment for particular clinical problems in type 1 diabetes. Most current guidelines (4,6) or reviews of the evidence base on CSII (2 …
Read more